Phaseline

Targets › CSF3

CSF3 (Granulocyte colony-stimulating factor): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 3; Oncology, Other, Genitourinary; next expected readout Dec 2026.

Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes. (UniProt, P09919)

Open in Phaseline: the race on CSF3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
First Affiliated Hospital of Zhejiang UniversityGranulocyte colony-stimulating factor (G-CSF)
G-CSF receptor agonist
CSF3Phase 3Healthy Hematopoietic Stem Cell DonorDec 2028
Shandong UniversityEfbemalenograstim Alfa
Granulocyte colony-stimulating factor (G-CSF) analog
CSF3Phase 2Ovarian CancerDec 2026
Fudan UniversityrhG-CSF + rhIL-11
Recombinant granulocyte-colony stimulating factor combined with recombinant interleukin-11
CSF3, IL11Phase 2Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)Dec 2026
Fakih IVF Fertility CenterRecombinant G-CSF
Granulocyte colony-stimulating factor receptor agonist
CSF3Phase 2Recurrent Pregnancy LossAug 2027

Conditions

Ovarian Cancer (1) Healthy Hematopoietic Stem Cell Donor (1) Recurrent Pregnancy Loss (1) Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB) (1)

Modalities

small molecule (3), protein or peptide (1)

Companies

Shandong University (1) First Affiliated Hospital of Zhejiang University (1) Fakih IVF Fertility Center (1) Fudan University (1)

Related targets

IL11 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.